Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial

American Journal of Hypertension

Volumn 16, Issue 6, 2003, Pages 460-466

  Giles, Thomas D ^a   Bakris, George L ^b   Smith, David H G ^c   Davidai, Giora ^d   Weber, Michael A ^e  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c Memorial Research Medical Clinic   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e SUNY Downstate Medical Center   (United States)

Author keywords

Angiotensin receptor blockade; Antihypertensive treatment; Hypertension; Telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; TELMISARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASTHENIA; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ETHNOLOGY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THORAX PAIN; TITRIMETRY;

EID: 0038204199     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(03)00848-3     Document Type: Article

References (19)

1. Messerli FH, Weir MR, Neutel JM: Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens 2002;15:550-556.
2. Kaplan NM: The CARE study: A postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Ther 1996;18:658-670.
3. Dzau V, Julius S, Weber MA: Validation of a large community based trial by nested study design: The ADOPT program. Am J Hypertens 1994;7:123A.
4. Weir MR, Weber MA, Neutel JM, Vendetti J, Brown C, Labarthe D: Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: A clinical experience trial. Am J Hypertens 2001;14:567-572.
5. Unger T, Chung O, Csikos T, Culman J, Zhu YZ: Angiotensin receptors. J Hypertens 1996;14(suppl 5):95-103.
6. Weber MA: Angiotensin II receptor blockers, in Izzo JL, Black HR (eds): Hypertension Primer, 3rd ed. Baltimore, Lippincott, Williams & Wilkins, 2003, pp 430-432.
7. Neutel JM, Smith DHG, for the Telmisartan US Study Group: Dose-response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998;15:206-217.
8. McGill JB, Rilly PA: Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazlde monotherapy in patients with mild to moderate hypertension: A multicenter, randomized, double-blind, placebo-controlled parallel-group trial. Clin Ther 2001;23:833-850.
9. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The Sixth Report. Arch Intern Med 1997;157:2413-2446.
10. Weber MA: Clinical experience with the angiotensin II receptor antagonist losartan: A preliminary report. Am J Hypertens 1992;5:247-251S.
11. Gillis JC, Markham A: Irbesartan: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in management of hypertension. Drugs 1997;54:885-902.
12. Burt VL, Whehon PK, Rocella EJ, Michelson E, Wang RY: Prevalence of hypertension in the US adult population: Results from the Third National Health and Nutrition Examination Survey 1988-1991. Hypertension 1995;25:305-313.
13. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, Moskowitz MA: Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339:1957-1963.
14. Laragh JH, Sealey JE, Niarchos AP, Pickering TG: The vasoconstriction-volume spectrum in normotension and patho-genesis of hypertension. Fed Proc 1982;41:2415-2423.
15. Roden DM, George AL Jr: The genetic basis of variability in drug responses. Nature Rev Drug Disc 2001;11:37-44.
16. Lacourciere Y, Lenis J, Orchard R, Lewanczuk R, Martin K: A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monitor 1998;3:295-302.
17. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
18. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE study group: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002;359:995-1003.
19. Ruddy MC, Kostis JB; Angiotensin II receptor antagonists, in Oparil S, Weber MA (eds.): Hypertension. Philadelphia, W.B. Saunders Co., 2000, pp 621-637.